Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence

References

• World Health Organization (WHO). Chronic obstructive pulmonary disease. Fact sheet #315, 2009. Available at: http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed February 11, 2010
   Google Scholar
• Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 2006;119:S4-11
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46-53s
   PubMedGoogle Scholar
• Donaldson GC, Seemungal TAR, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931-936
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J COPD 2008;3:71-88
   Google Scholar
• Ramsay SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003;41:29s-35s
   Google Scholar
• Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
   Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respire Crit Care Med 2007;176:532-555
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J 2007;14 (Suppl B):5B-32B
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. NICE guideline: chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease for adults in primary and secondary care. National Institute for Clinical Excellence, NHS, Clinical Guideline 12, February 2004
   Google Scholar
• Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;147:633-638
   PubMed Web of Science ®Google Scholar
• Programm fur Nationale VersoorgungsLeitlinie. COPD Langfassung, Version 1.7. February 2010. Available at: http://www.versorgungsleitlinien.de/themen/copd/pdf/nvl_copd_lang.pdf. Accessed June 1, 2010
   Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002;19:209-216
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010;35:287-294
   PubMed Web of Science ®Google Scholar
• PubMed [Web site]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed May 26, 2010
   Google Scholar
• The Cochrane Library [Web site]. Available at: http://www.thecochranelibrary.com. Accessed May 26, 2010
   Google Scholar
• EMBASE [Web site]. Available at: http://library.dialog.com/bluesheets/html/bl0072.html. Accessed May 26, 2010
   Google Scholar
• Oostenbrink JB, Rutten-van Molken M, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46
   PubMed Web of Science ®Google Scholar
• Schramm W, Haake D, Brandt A. Economic value of tiotropium (Spiriva®) in the treatment of chronic obstructive pulmonary disease. Praxis 2005;94:1803-1810
   PubMedGoogle Scholar
• Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22:1599-1607
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-135
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Maiwenn J, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008;11:1070-1080
   PubMed Web of Science ®Google Scholar
• Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-749
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Molken MP, van Noord JA, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241-249
   PubMed Web of Science ®Google Scholar
• Ramos P de Lucas, Miravitlles M, Gonzalez-Moro JM, et al. Cost-effectiveness analysis of the use of tiotropium compared with ipratropium in the treatment of patients with chronic obstructive pulmonary disease. PharmacoEconomics Spanish Research Articles 2004;1:121-128
   Google Scholar
• Sanz-Martinez H, Perez-Maroto MT. Cost-efficacy analysis of tiotropium versus ipratropium and salmeterol in the treatment of chronic obstructive pulmonary disease. Farmacia Aten Primaria 2004;2:72-82
   Google Scholar
• Garcia Ruiz AJ, Leiva Fernandez F, Martos Crespo F. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch Bronconeumol 2005;41:242-248
   PubMed Web of Science ®Google Scholar
• Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007;82:575-582
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63:962-967
   PubMed Web of Science ®Google Scholar
• Reynoso FN. Effect of inhaled salbutamol-ipratropium and salbutamol-tiotropium combinations and oral theophylline in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Rev Inst Nal Enf Resp Mex 2006;19:122-126
   Google Scholar
• Sicras-Mainar A, Velasco-Velasco S, Llopart-Lopez JR, et al. Calculation of morbidity, use of resources and costs of patients treated with tiotropium bromide for COPD in a Spanish population. Aten Primaria 2007;39:547-555
   PubMed Web of Science ®Google Scholar
• Drescher GS, Carnathan BJ, Imus S, et al. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs. Respir Care 2008;53:1678-1684
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Mullins CD, DeLisle S. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs Health Care System. Value Health 2008;11:980-988
   PubMed Web of Science ®Google Scholar
• Dalal A, Petersen H, Simoni-Wastila L, et al. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 µg/salmeterol 50 µg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ 2009;12:339-347
   PubMedGoogle Scholar
• Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009;29:891-905
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, UK: Oxford University Press, 2005:211–245
   Google Scholar
• Sculpher M. Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease. Pharmacoeconomics 2001;19(Suppl 2):21-25
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996:82–134
   Google Scholar
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care). IQWiG methods for assessment of the relation of benefits to costs in the German statutory health care system, version 1.1, 2008
   Google Scholar
• Rutten-van Molken MP, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2003;3:630-634
   Google Scholar